Effect of convalescent plasma as complementary treatment in patients with moderate COVID-19 infection
Baldeón et al.,
Effect of convalescent plasma as complementary treatment in patients with moderate COVID-19 infection,
Transfusion Medicine, doi:10.1111/tme.12851
RCT 158 patients in Ecuador, showing no significant difference in mortality with convalescent plasma. Authors note indications of improved results for earlier treatment.
risk of death, 12.0% lower, RR 0.88, p = 1.00, treatment 7 of 63 (11.1%), control 12 of 95 (12.6%), NNT 66.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Baldeón et al., 9 Jan 2022, Double Blind Randomized Controlled Trial, placebo-controlled, Ecuador, peer-reviewed, 17 authors.
Contact:
mabaldeonti@uide.edu.ec.
Abstract: See discussions, stats, and author profiles for this publication at: https://www.researchgate.net/publication/357709366
Effect of convalescent plasma as complementary treatment in patients with
moderate COVID ‐19 infection
Article in Transfusion Medicine · January 2022
DOI: 10.1111/tme.12851
CITATIONS
READS
5
31
17 authors, including:
Manuel Baldeon
Augusto Maldonado
Universidad Internacional del Ecuador
Universidad San Francisco de Quito (USFQ)
89 PUBLICATIONS 1,121 CITATIONS
19 PUBLICATIONS 64 CITATIONS
SEE PROFILE
SEE PROFILE
Miguel Jacob Ochoa Andrade
Francisco Xavier Mora Toro
Central University of Ecuador
Instituto Ecuatoriano de Seguridad Social
12 PUBLICATIONS 5 CITATIONS
11 PUBLICATIONS 66 CITATIONS
SEE PROFILE
Some of the authors of this publication are also working on these related projects:
LMC-Helicobacter View project
Chronic non-communicable diseases View project
All content following this page was uploaded by Augusto Maldonado on 22 June 2022.
The user has requested enhancement of the
SEE PROFILE
Received: 8 September 2021
Revised: 13 December 2021
Accepted: 30 December 2021
DOI: 10.1111/tme.12851
ORIGINAL ARTICLE
Effect of convalescent plasma as complementary treatment in
patients with moderate COVID-19 infection
n1
Manuel E. Baldeo
|
Augusto Maldonado2,3
|
Miguel Ochoa-Andrade4 |
nica Pesantez5 | Marco Herdoiza5 | Gerardo Granja4 |
Carolina Largo3 | Mo
pez3 |
Marco Bonifaz4 | Hugo Espejo4 | Francisco Mora4 | Patricio Abril-Lo
nica Pacheco6 | Rafael Salazar6 |
Lady Karen Robles Armijo6 | Vero
Steffy Reinthaller6
| Federico Zertuche7
1
Escuela de Medicina, Facultad de Ciencias
Médicas, de la Salud y de la Vida, Universidad
Internacional del Ecuador, Quito, Ecuador
|
Marco Fornasini1
Abstract
Introduction: South America is one of the regions most affected by the COVID-19
2
Escuela de Medicina, Colegio de Ciencias de
la Salud, Universidad San Francisco de Quito,
Quito, Ecuador
n
Ministerio de Salud Pública, Coordinacio
Zonal 9, Hospital General Docente de
n, Quito, Ecuador
Caldero
3
4
Instituto Ecuatoriano de Seguridad Social,
Hospital General Quito Sur - IESS, Quito,
Ecuador
5
Hemocentro, Cruz Roja Ecuatoriana, Quito,
Ecuador
n
Ministerio de Salud Pública, Coordinacio
Zonal 9, Hospital Pablo Arturo Suarez, Quito,
Ecuador
6
pandemic. Specific and affordable treatments are needed to treat SARS-CoV-2 infection. Evidence regarding the use of convalescent plasma in COVID-19 patients is still
limited. We compared the safety and efficacy of COVID-19-convalescent plasma
administration as a complement to standard treatment in the early management of
patients with moderate SARS-CoV-2 infection.
Methods: We carried out a random double blinded, placebo-controlled trial that compared standard treatment plus convalescent plasma (CP) or plus non-convalescent
plasma in the management of COVID-19 patients. The main outcome was survival
and secondary endpoints included: length of hospitalisation (LOH), days from treatment to discharge, time to clinical improvement or death within a 28-day period, and
Facultad de Ciencias de la Salud Eugenio
Espejo, Universidad UTE, Quito, Ecuador
adverse reactions to treatment.
Correspondence
n, Escuela de Medicina,
Manuel E. Baldeo
survival, RR = 1.003, 95% CI (0.3938, 2.555). These results led to terminate the RCT pre-
7
Facultad de Ciencias Médicas, de la Salud y de
la Vida, Universidad Internacional del Ecuador,
n..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit